Skip to content

Commit 4bd85ae

Browse files
jfkonecnjfkonecn
authored
v6.1 (#1302)
* v6.1
1 parent 5890055 commit 4bd85ae

File tree

9 files changed

+288
-3
lines changed

9 files changed

+288
-3
lines changed

‎src/main/webapp/app/config/constants.tsx‎

Lines changed: 1 addition & 0 deletions
Original file line numberDiff line numberDiff line change
@@ -904,6 +904,7 @@ export type DataRelease = {
904904
};
905905

906906
export const DATA_RELEASES: DataRelease[] = [
907+
{ date: '01292026', version: 'v6.1' },
907908
{ date: '12182025', version: 'v6.0' },
908909
{ date: '11242025', version: 'v5.4' },
909910
{ date: '10082025', version: 'v5.3' },

‎src/main/webapp/app/pages/newsPage/NewsPage.tsx‎

Lines changed: 1 addition & 0 deletions
Original file line numberDiff line numberDiff line change
@@ -86,6 +86,7 @@ export default class NewsPage extends React.Component<{
8686
<CitationText />
8787
</div>
8888
<div className="mt-2">
89+
<NewsList date={'01292026'} />
8990
<NewsList date={'12182025'} />
9091
<NewsList date={'11242025'} />
9192
<NewsList date={'10082025'} />

‎src/main/webapp/app/pages/newsPage/NewsPageContent.tsx‎

Lines changed: 4 additions & 0 deletions
Original file line numberDiff line numberDiff line change
@@ -56,6 +56,7 @@ import NewsContent092025 from './code-generated/NewsContent092025';
5656
import NewsContent102025 from './code-generated/NewsContent102025';
5757
import NewsContent112025 from './code-generated/NewsContent112025';
5858
import NewsContent122025 from './code-generated/NewsContent122025';
59+
import NewsContent012026 from './code-generated/NewsContent012026';
5960

6061
export type ChangedAnnotation = {
6162
content: (ElementType | ElementType[])[][];
@@ -313,6 +314,9 @@ const EVIDENCE_COLUMN_SEPARATOR = '; ';
313314
// https://stackoverflow.com/questions/41947168/is-it-possible-to-use-keyof-operator-on-literals-instead-of-interfaces
314315

315316
export const NEWS_BY_DATE: { [date: string]: NewsData } = {
317+
'01292026': {
318+
rawComponent: <NewsContent012026 />,
319+
},
316320
'12182025': {
317321
rawComponent: <NewsContent122025 />,
318322
},

‎src/main/webapp/app/pages/newsPage/NewsPageNavTab.tsx‎

Lines changed: 1 addition & 1 deletion
Original file line numberDiff line numberDiff line change
@@ -17,7 +17,7 @@ export enum TabKey {
1717
YEAR_END_SUMMARY = PAGE_ROUTE.YEAR_END_SUMMARY,
1818
}
1919

20-
export const YEAR_END_SUMMARY_RANGE = ['2024', '2023', '2022'] as const;
20+
export const YEAR_END_SUMMARY_RANGE = ['2025', '2024', '2023', '2022'] as const;
2121
const HASH_KEY_DIVIDER = '+';
2222

2323
@inject('appStore', 'routing')

‎src/main/webapp/app/pages/newsPage/code-generated/NewsContent012026.tsx‎

Lines changed: 99 additions & 0 deletions
Original file line numberDiff line numberDiff line change
@@ -0,0 +1,99 @@
1+
import React from 'react';
2+
import { Link } from 'react-router-dom';
3+
import {
4+
AlterationPageLink,
5+
getAlternativeGenePageLinks,
6+
GenePageLink,
7+
} from 'app/shared/utils/UrlUtils';
8+
import { NewlyAddedGenesListItem } from 'app/pages/newsPage/NewlyAddedGenesListItem';
9+
import { TableOfContents } from 'app/pages/privacyNotice/TableOfContents';
10+
11+
export default function NewsContent012026() {
12+
return (
13+
<>
14+
<ul>
15+
<li>
16+
We hope everyone is having a great start to the new year! In 2025
17+
OncoKB added fifteen Level 1, eight Level 2, one Level 3 and one Level
18+
4 treatments for unique biomarker-selected indications to the
19+
database. A table summarizing these changes can be found{' '}
20+
<Link to="/year-end-summary#2025">here</Link>. For more details,
21+
please see the “Precision Oncology: 2025 in Review” article, found{' '}
22+
<a href="https://aacrjournals.org/cancerdiscovery/article-abstract/15/12/2414/767704/Precision-Oncology-2025-in-ReviewPrecision?">
23+
here
24+
</a>
25+
</li>
26+
</ul>
27+
<p>
28+
<strong>Updated Therapeutic Implications</strong>
29+
</p>
30+
<ul>
31+
<li>
32+
Addition of drug(s) associated with a tumor type-specific leveled
33+
alteration(s) currently in OncoKB™ (without changing the alteration's
34+
highest level of evidence)
35+
</li>
36+
</ul>
37+
<div className="table-responsive">
38+
<table className="table">
39+
<thead>
40+
<tr>
41+
<th>Level</th>
42+
<th>Gene</th>
43+
<th>Mutation</th>
44+
<th>Cancer Type</th>
45+
<th>Level-Associated Drug(s) in OncoKB™</th>
46+
<th>Drug(s) Added to OncoKB™</th>
47+
<th>Evidence</th>
48+
</tr>
49+
</thead>
50+
<tbody>
51+
<tr>
52+
<td>1</td>
53+
<td>{getAlternativeGenePageLinks('ERBB2')}</td>
54+
<td>
55+
<AlterationPageLink
56+
hugoSymbol="ERBB2"
57+
alteration="Amplification"
58+
>
59+
Amplification
60+
</AlterationPageLink>
61+
</td>
62+
<td>Breast Cancer</td>
63+
<td>
64+
Trastuzumab, Trastuzumab Deruxtecan, Ado-Trastuzumab Emtansine,
65+
Margetuximab, Neratinib, Lapatinib, Trastuzumab + Pertuzumab,
66+
Trastuzumab + Tucatinib (Level 1)
67+
</td>
68+
<td>Trastuzumab Deruxtecan + Pertuzumab (Level 1)</td>
69+
<td>
70+
<a href="https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-fam-trastuzumab-deruxtecan-nxki-pertuzumab-unresectable-or-metastatic-her2-positive">
71+
FDA approval of trastuzumab deruxtecan with pertuzumab
72+
</a>
73+
; PMID:{' '}
74+
<a href="https://pubmed.ncbi.nlm.nih.gov/41160818/">41160818</a>
75+
</td>
76+
</tr>
77+
</tbody>
78+
</table>
79+
</div>
80+
<ul>
81+
<li>
82+
<NewlyAddedGenesListItem
83+
genes={[
84+
'AAMP',
85+
'APCDD1',
86+
'ASXL3',
87+
'BACH1',
88+
'ESCO1',
89+
'FCGR2B',
90+
'H4C9',
91+
'HIP1',
92+
'PAFAH1B2',
93+
]}
94+
></NewlyAddedGenesListItem>
95+
</li>
96+
</ul>
97+
</>
98+
);
99+
}

‎src/main/webapp/app/pages/newsPage/markdown/NewsContent012026.md‎

Lines changed: 20 additions & 0 deletions
Original file line numberDiff line numberDiff line change
@@ -0,0 +1,20 @@
1+
- We hope everyone is having a great start to the new year\! In 2025 OncoKB added fifteen Level 1, eight Level 2, one Level 3 and one Level 4 treatments for unique biomarker-selected indications to the database. A table summarizing these changes can be found [here](https://www.oncokb.org/year-end-summary#2025). For more details, please see the “Precision Oncology: 2025 in Review” article, found [here](https://aacrjournals.org/cancerdiscovery/article-abstract/15/12/2414/767704/Precision-Oncology-2025-in-ReviewPrecision?)
2+
3+
**Updated Therapeutic Implications**
4+
5+
- Addition of drug(s) associated with a tumor type-specific leveled alteration(s) currently in OncoKB™ (without changing the alteration's highest level of evidence)
6+
7+
| Level | Gene | Mutation | Cancer Type | Level-Associated Drug(s) in OncoKB™ | Drug(s) Added to OncoKB™ | Evidence |
8+
| :---- | :---- | :------------ | :------------ | :----------------------------------------------------------------------------------------------------------------------------------------------------------------- | :---------------------------------------------- | :----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
9+
| 1 | ERBB2 | Amplification | Breast Cancer | Trastuzumab, Trastuzumab Deruxtecan, Ado-Trastuzumab Emtansine, Margetuximab, Neratinib, Lapatinib, Trastuzumab \+ Pertuzumab, Trastuzumab \+ Tucatinib (Level 1\) | Trastuzumab Deruxtecan \+ Pertuzumab (Level 1\) | [FDA approval of trastuzumab deruxtecan with pertuzumab](https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-fam-trastuzumab-deruxtecan-nxki-pertuzumab-unresectable-or-metastatic-her2-positive); PMID: [41160818](https://pubmed.ncbi.nlm.nih.gov/41160818/) |
10+
11+
- Addition of 9 new genes:
12+
- AAMP
13+
- APCDD1
14+
- ASXL3
15+
- BACH1
16+
- ESCO1
17+
- FCGR2B
18+
- H4C9
19+
- HIP1
20+
- PAFAH1B2

‎src/main/webapp/app/pages/yearEndSummaryPage/BiomarkerTableData.tsx‎

Lines changed: 160 additions & 0 deletions
Original file line numberDiff line numberDiff line change
@@ -7,6 +7,166 @@ import {
77
import { LEVELS } from 'app/config/constants';
88

99
export const DATA: { [key in TableKey]: TableData } = {
10+
'2025': {
11+
[LEVELS.Tx1]: [
12+
[
13+
'ALK Fusions',
14+
'Non-Small Cell Lung Cancer',
15+
'Ensartinib',
16+
'Addition of a novel drug to an existing Level 1 clinically actionable biomarker',
17+
],
18+
[
19+
'KRAS G12C',
20+
'Colorectal Cancer',
21+
'Sotorasib + Panitumumab',
22+
'Addition of a novel drug to an existing Level 1 clinically actionable biomarker',
23+
],
24+
[
25+
'BRAF V600E',
26+
'Colorectal Cancer',
27+
'Encorafenib + Cetuximab + FOLFOX Regimen',
28+
'Addition of a novel drug to an existing Level 1 clinically actionable biomarker',
29+
],
30+
[
31+
'NF1 Oncogenic mutations',
32+
'Neurofibroma',
33+
'Mirdametinib',
34+
'Addition of a novel drug to an existing Level 1 clinically actionable biomarker',
35+
],
36+
[
37+
'KRAS Oncogenic mutations',
38+
'Low-Grade Serous Ovarian Cancer',
39+
'Avutometinib + Defactinib',
40+
'Novel Level 1 clinically actionable biomarker',
41+
],
42+
[
43+
'ROS1 Fusions',
44+
'Non-Small Cell Lung Cancer',
45+
'Taletrectinib',
46+
'Addition of a novel drug to an existing Level 1 clinically actionable biomarker',
47+
],
48+
[
49+
'EGFR Oncogenic mutations ',
50+
'Non-Small Cell Lung Cancer',
51+
'Datopotamab Deruxtecan',
52+
'Addition of a novel drug to an existing Level 1 clinically actionable biomarker *note previously only select EGFR oncogenic mutations were Level 1',
53+
],
54+
[
55+
'EGFR Exon 20 in-frame insertions',
56+
'Non-Small Cell Lung Cancer',
57+
'Sunvozertinib',
58+
'Addition of a novel drug to an existing Level 1 clinically actionable biomarker',
59+
],
60+
[
61+
'ERBB2 Activating mutations in the tyrosine kinase domain ',
62+
'Non-Small Cell Lung Cancer',
63+
'Zongertinib, Sevabertinib',
64+
'Addition of a novel drug to an existing Level 1 clinically actionable biomarker',
65+
],
66+
[
67+
'H3-3A K28M',
68+
'Diffuse Midline Glioma, H3 K27-Altered',
69+
'Dordaviprone',
70+
'Novel Level 1 clinically actionable biomarker',
71+
],
72+
73+
[
74+
'H3C2 K28M',
75+
'Diffuse Midline Glioma, H3 K27-Altered',
76+
'Dordaviprone',
77+
'Novel Level 1 clinically actionable biomarker',
78+
],
79+
80+
[
81+
'H3C3 K28M',
82+
'Diffuse Midline Glioma, H3 K27-Altered',
83+
'Dordaviprone',
84+
'Novel Level 1 clinically actionable biomarker',
85+
],
86+
87+
[
88+
'ESR1 S463P, L469V, L536, Y537, D538, E380, V422del, S463F',
89+
'Breast Cancer',
90+
'Imlunestrant',
91+
'Addition of a novel drug to an existing Level 1 clinically actionable biomarker',
92+
],
93+
94+
[
95+
'NPM1 Susceptible mutations (Truncating mutations in exons 5, 9, 11; Select exon 5 indels; Select NPM1 fusions) ',
96+
'Acute Myeloid Leukemia',
97+
'Ziftomenib, Revumenib',
98+
'Novel Level 1 clinically actionable biomarker',
99+
],
100+
],
101+
[LEVELS.Tx2]: [
102+
[
103+
'ERBB2 Oncogenic mutations',
104+
'Cervical Cancer',
105+
'Neratinib',
106+
'Novel clinically actionable biomarker in this cancer type',
107+
],
108+
109+
[
110+
'KRAS G12C',
111+
'Small Bowel Cancer',
112+
'Adagrasib, Sotorasib',
113+
'Level promotion for an existing biomarker-tumor type-drug association',
114+
],
115+
[
116+
'FGFR1 Fusions',
117+
'Pancreatic Cancer',
118+
'Erdafitinib',
119+
'Level promotion for an existing biomarker-tumor type-drug association',
120+
],
121+
[
122+
'FGFR2 Fusions',
123+
'Pancreatic Cancer',
124+
'Erdafitinib',
125+
'Level promotion for an existing biomarker-tumor type-drug association',
126+
],
127+
[
128+
'FGFR2 Oncogenic mutations',
129+
'Non-Small Cell Lung Cancer',
130+
'Erdafitinib',
131+
'Level promotion for an existing biomarker-tumor type-drug association',
132+
],
133+
[
134+
'FGFR3 Oncogenic mutations',
135+
'Non-Small Cell Lung Cancer',
136+
'Erdafitinib',
137+
'Level promotion for an existing biomarker-tumor type-drug association',
138+
],
139+
[
140+
'ERBB2 Oncogenic mutations',
141+
'Breast Cancer',
142+
'Neratinib + Trastuzumab + Fulvestrant',
143+
'Addition of a novel drug to an existing clinically actionable biomarker',
144+
],
145+
146+
[
147+
'ERBB2 Oncogenic mutations (excluding select activating mutations in the tyrosine kinase domain)',
148+
'Non-Small Cell Lung Cancer',
149+
'Zongertinib',
150+
'Addition of a novel drug to an existing clinically actionable biomarker',
151+
],
152+
],
153+
[LEVELS.Tx3]: [
154+
[
155+
'ERBB2 Oncogenic mutations (excluding select activating mutations in the tyrosine kinase domain)',
156+
'Non-Small Cell Lung Cancer',
157+
'Sevabertinib',
158+
'Addition of a novel drug to an existing clinically actionable biomarker',
159+
],
160+
],
161+
[LEVELS.Tx4]: [
162+
[
163+
'ERBB2 Oncogenic mutations',
164+
'Biliary Tract Cancer',
165+
'Neratinib, Trastuzumab Deruxtecan, Pertuzumab + Trastuzumab',
166+
'Novel clinically actionable biomarker in this cancer type',
167+
],
168+
],
169+
},
10170
'2024': {
11171
[LEVELS.Tx1]: [
12172
[

‎src/main/webapp/content/images/oncokb_summary.png‎

-234 KB
Loading

‎src/main/webapp/index.html‎

Lines changed: 2 additions & 2 deletions
Original file line numberDiff line numberDiff line change
@@ -14,15 +14,15 @@
1414
<meta name="twitter:site" content="@oncokb">
1515
<meta name="twitter:title" content="OncoKB™ - MSK's Precision Oncology Knowledge Base">
1616
<meta name="twitter:description" content="OncoKB™ is a precision oncology knowledge base developed at Memorial Sloan Kettering Cancer Center that contains biological and clinical information about genomic alterations in cancer.">
17-
<meta name="twitter:image" content="https://www.oncokb.org/content/images/oncokb_summary.png?20251218">
17+
<meta name="twitter:image" content="https://www.oncokb.org/content/images/oncokb_summary.png?20260129">
1818
<meta name="twitter:url" content="https://www.oncokb.org/">
1919

2020
<meta property="og:site_name" content="OncoKB™">
2121
<meta property="og:type" content="website">
2222
<meta property="og:url" content="https://www.oncokb.org/">
2323
<meta property="og:title" content="OncoKB™ - MSK's Precision Oncology Knowledge Base">
2424
<meta property="og:description" content="OncoKB™ is a precision oncology knowledge base developed at Memorial Sloan Kettering Cancer Center that contains biological and clinical information about genomic alterations in cancer.">
25-
<meta property="og:image" content="https://www.oncokb.org/content/images/oncokb_summary.png?20251218">
25+
<meta property="og:image" content="https://www.oncokb.org/content/images/oncokb_summary.png?20260129">
2626
<meta name="google-site-verification" content="ibij2JbakmZzcd7E_bipKn1xrEM-fAewA1podDE11Jg" />
2727

2828
<link rel="mask-icon" href="content/images/favicon/safari-pinned-tab.svg" color="#0968c3">

0 commit comments

Comments
 (0)